Company intelligence / Profile preview

StemCore

Seongnam, Gyeonggi-do, South Korea

Ownership: Private
Employees: ~25
Development stage: Other

Overview

StemCore is a South Korean clinical-stage biotechnology company specializing in the development of advanced stem cell therapies for degenerative and traumatic diseases. The company utilizes its proprietary StemCore Platform to isolate high-purity mesenchymal and neural stem cells for large-scale production, addressing the challenges of cell population heterogeneity. Its lead candidate, SC-SCI, is currently undergoing Phase 1/2a clinical evaluation for the treatment of spinal cord injury. StemCore's broader pipeline includes preclinical programs targeting stroke, osteoarthritis, and liver cirrhosis, aiming to provide regenerative solutions for conditions with high unmet medical needs.

Therapeutic areas: RheumatologyNeurologyGastroenterology
Modalities: Stem cell therapyCell therapy
Industry: Biotech

Beyond the preview

Go deeper on StemCore.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on StemCore.

Explore the full profile